---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-018482"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T09:58:52.875844+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cassava shareholders reject board declassification; director pay raised

## Summary
- Proposal to reduce board classification from 3 to 2 classes failed despite 91% of votes cast in favor, lacking 66 2/3% of outstanding shares.
- Non-employee director annual cash retainer increased from $10,000 to $40,000; Board Chair gets additional $30,000.
- Annual stock option grant for continuing directors raised from 10,000 to 26,500 shares; initial grants rise to 53,000.
- Audit, Compensation, and Nominating Committee chairs receive $15,000, $10,000, and $8,000 annual cash fees respectively.
- Two directors elected: Robert Anderson, Jr. (5.64M for) and Michael J. O'Donnell (4.54M for) to three-year terms.

## SEC filing metadata
- accession: 0001437749-25-018482
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774925018482/0001437749-25-018482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774925018482/sava20250523_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-018482
- JSON: https://secwatch.observer/filing/0001437749-25-018482.json
- Plain text: https://secwatch.observer/filing/0001437749-25-018482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.